Version May 2024
Note: To minimize radioactive iodine uptake by the thyroid gland, thyroid protective agents (eg, Lugol's solution, potassium iodide) may be administered at least 24 hours prior to administration of iodinated I 131 albumin and continued for 1 to 2 weeks thereafter.
Protein turnover studies (Volumex): IV: 10 to 150 microcuries (0.37 to 5.55 MBq). Note: Allow a period of 7 days post injection before making determinations.
Total blood and plasma volume detection: IV: 5 to 50 microcuries (0.185 to 1.85 MBq); maximum: if a procedure needs to be repeated, do not exceed 200 microcuries (7.4 MBq) in any one week.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not defined: Miscellaneous: Hypersensitivity reactions
There are no contraindications listed in the manufacturer's labeling.
Special handling:
• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.
Other warnings/precautions:
• Appropriate use: Cisternography: Aseptic meningeal irritation and hyperpyrexia have been reported following use in cisternography. Iodinated I 131 albumin is not approved for use in cisternography.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous:
Megatope: 1 mCi/mL (8 mL) [contains benzyl alcohol]
Solution Prefilled Syringe, Intravenous:
Volumex: 25 mcCi/mL (1 ea) [contains benzyl alcohol]
Yes
For IV administration. Radiopharmaceutical; use appropriate precautions for handling and disposal.
Imaging agent: Determination of total blood and plasma volumes (Megatope and Volumex) and in protein turnover studies (Volumex).
Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.
The manufacturer recommends that elective procedures done in women of reproductive potential be conducted within the first few (~10) days following onset of menses.
Animal reproduction studies have not been conducted. If treatment is required for localization of the placenta, pretreatment with Lugol's solution is required to decrease exposure to the fetus.
It is not known if iodinated I 131 albumin is present in breast milk; however, free I 131 (eg, from metabolism/deiodination of the product) is present in breast milk. The manufacturer recommends substituting formula for breast milk if therapy is needed in breastfeeding women.
Onset of action: Within 10 minutes.
Half-life elimination: Physical: 8.02 days (Megatope); 8.08 days (Volumex); Biological: ~14 days.
Excretion: Urine; feces (~2%).
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
